|Mr. Leonard S. Ross||Principal Financial & Accounting Officer and VP of Fin.||N/A||N/A||67|
|Ms. Nancy S. Lurker||CEO, Pres & Director||N/A||N/A||60|
|Mr. Marty Nazzaro||VP of Operations||N/A||N/A||N/A|
|Ms. Deborah A. Jorn||Exec. VP of Corp. and Commercial Devel.||N/A||N/A||59|
|Dr. Dario A. Paggiarino M.D.||Chief Medical Officer||N/A||N/A||60|
pSivida Corp. develops sustained-release drug-delivery products for the treatment of chronic eye diseases in the United States and the United Kingdom. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior segment uveitis. The company is also developing Medidur, an injectable, sustained-release micro-insert, which is in Phase III clinical trials for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Its pre-clinical development program focuses on developing products using its core platform technologies, Durasert and Tethadur, to deliver drugs and biologics to treat wet and dry age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. The company has strategic collaborations with Alimera Sciences, Inc.; Pfizer, Inc.; Bausch & Lomb Incorporated; and Enigma Therapeutics Limited. pSivida Corp. was founded in 1987 and is headquartered in Watertown, Massachusetts.
pSivida Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.